Who is sponsoring NCT02962401?

NCT02962401 is sponsored by French Innovative Leukemia Organisation.

What drugs are being tested in NCT02962401?

Interventions in NCT02962401: Obinutuzumab, Idelalisib.

What condition does NCT02962401 study?

NCT02962401 studies Waldenstrom Macroglobulinemia.

Is NCT02962401 still recruiting?

NCT02962401 is currently completed. Last updated 29 August 2023.

Last reviewed 2023-08-29 · How we verify

NCT02962401: RemodelWM3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Completed Phase 2 Last updated 29 August 2023

What this trial tests

Phase 2 trial testing Obinutuzumab in Waldenstrom Macroglobulinemia in 50 participants. Completed in 13 April 2023.

Timeline

7 March 2017

Primary endpoint
31 August 2020

13 April 2023

Quick facts

Lead sponsor	French Innovative Leukemia Organisation
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	7 March 2017
Primary completion	31 August 2020
Estimated completion	13 April 2023
Sites	1 location across France

Drugs / interventions tested

Obinutuzumab — full drug profile →
Idelalisib — full drug profile →

Conditions studied

Waldenstrom Macroglobulinemia — all drugs for Waldenstrom Macroglobulinemia →

Sponsor

French Innovative Leukemia Organisation — full company profile →

Who can join

18 and older, any sex, with Waldenstrom Macroglobulinemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective national multicenter open label phase II Remodel WM3 trial

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J, Nie J, Ma X, Wei Y, et al · · 2019 · cited 1142× · PMID 30782187 · DOI 10.1186/s12943-019-0954-x
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
Mishra R, Patel H, Alanazi S, Kilroy MK, et al · · 2021 · cited 207× · PMID 33801659 · DOI 10.3390/ijms22073464
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia.
Tomowiak C, Poulain S, Herbaux C, Perrot A, et al · · 2021 · cited 21× · PMID 33961019 · DOI 10.1182/bloodadvances.2020003895
Management of Waldenström macroglobulinemia in 2020.
Castillo JJ, Treon SP. · · 2020 · cited 21× · PMID 33275726 · DOI 10.1182/hematology.2020000121
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A, Herter S, Grosmaire L, Jones R, et al · · 2018 · cited 15× · PMID 29453281 · DOI 10.4049/jimmunol.1700323
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.
Tomowiak C, Poulain S, Nudel M, Feugier P, et al · · 2025 · cited 2× · PMID 39499299 · DOI 10.1007/s00277-024-06076-1
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström’s macroglobulinemia
Tomowiak C, Poulain S, Nudel M, Feugier P, et al · · 2024 · DOI 10.21203/rs.3.rs-4978701/v1

Verify or expand the search:

Other trials of Obinutuzumab

Trials testing the same drug.

NCT07003295 — Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease R · Phase 2 · recruiting
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07480850 — Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma · Phase 2 · active not recruiting
NCT07261163 — Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · Phase 2 · not yet recruiting

Other recruiting trials for Waldenstrom Macroglobulinemia

Currently open trials in the same condition.

NCT07231952 — A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacyti · Phase 2 · recruiting
NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting
NCT06561347 — Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM · Phase 2 · recruiting
NCT06510491 — Epcoritamab in Previously Treated WM · Phase 2 · recruiting
NCT06151730 — Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies U · recruiting

Other French Innovative Leukemia Organisation trials

Trials by the same sponsor.

NCT07007052 — Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Bl · Phase 2 · not yet recruiting
NCT06547866 — Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated f · Phase 2 · not yet recruiting
NCT06377579 — OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia · recruiting
NCT06263387 — Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible · recruiting
NCT06186648 — Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter S · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02962401 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by French Innovative Leukemia Organisation
Last refreshed: 29 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02962401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing